Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis

Journal of Infection

Volumn 53, Issue 2, 2006, Pages 131-139

  Sionov, Edward ^a   Mendlovic, Sonia ^b   Segal, Esther ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b ASSAF HAROFEH MEDICAL CENTER   (Israel)

Author keywords

Amphotericin B; Amphotericin B intralipid; Aspergillosis; Caspofungin; Combination therapy

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CYCLOPHOSPHAMIDE; GALACTOMANNAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CELL MEMBRANE; CELL WALL; CONIDIUM; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; EXPERIMENTAL INFECTION; FUNGAL CELL; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; SURVIVAL RATE;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; DRUG THERAPY, COMBINATION; ECHINOCANDINS; FEMALE; LUNG DISEASES, FUNGAL; MICE; MICE, INBRED ICR; PEPTIDES, CYCLIC;

EID: 33745872906     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2005.10.015     Document Type: Article

References (29)

1. Denning D.W. Invasive aspergillosis. Clin Infect Dis 26 (1998) 781-803
2. Kontoyiannis D.P., and Bodey G.P. Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis 21 (2002) 161-172
3. Kontoyiannis D.P., Mantadakis E., and Samonis G. Systemic mycoses in the immunocompromised host: an update in antifungal therapy. J Hosp Infect 53 (2003) 243-258
4. Denning D.W. Aspergillus species. In: Mandell G.L., Bennett J.E., and Dolin R. (Eds). Principles and practice of infectious diseases. 5th ed. vol. 2 (2000), Churchill Livingstone 2674-2685
5. Latge J.P. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 12 (1999) 310-350
6. Denning D.W. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 23 (1996) 608-615
7. Kontoyiannis D.P., and Lewis R.E. Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far. Drug Resist Updat 6 (2003) 257-269
8. Lin S.J., Schranz J., and Teutsch S.M. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 32 (2001) 358-366
9. Patterson T.F., Kirkpatrick W.R., White M., Hiemenz J.W., Wingard J.R., Dupont B., et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus study group. Medicine (Baltimore) 79 (2000) 250-260
10. Shadkhan Y., Segal E., Bor A., Gov Y., Rubin M., and Lichtenberg D. The use of commercially available lipid emulsions for the preparation of amphotericin B-lipid admixtures. J Antimicrob Chemother 39 (1997) 655-658
11. Shadkhan Y., and Segal E. Antifungal activity of amphotericin B-lipid admixtures in experimental systemic candidosis in naive mice. J Antimicrob Chemother 44 (1999) 787-790
12. Shadkhan Y., and Segal E. Treatment of experimental candidosis with amphotericin B-intralipid admixtures in immunocompromised mice. J Antimicrob Chemother 48 (2001) 245-251
13. Sionov E., and Segal E. Treatment of murine systemic aspergillosis with polyene-intralipid admixtures. Med Mycol 42 (2004) 73-80
14. Schadkchan Y., Zaslavsky Z., and Segal E. Pharmacokinetics of amphotericin B in serum and tissues in mice treated with amphotericin B-intralipid. Med Mycol 41 (2003) 15-19
15. Bowman J.C., Hicks P.S., Kurtz M.B., Rosen H., Schmatz D.M., Liberator P.A., et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 46 (2002) 3001-3012
16. Groll A.H., and Walsh T.J. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Investig Drugs 10 (2001) 1545-1558
17. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi; approved standard. NCCLS document M38-A (2000), NCCLS, Wayne, PA
18. Arikan S., Lozano-Chiu M., Paetznick V., and Rex J.H. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 46 (2002) 245-247
19. Sionov E., and Segal E. Polyene and cytokine treatment of experimental aspergillosis. FEMS Immunol Med Microbiol 39 (2003) 221-227
20. Ikeda F., Wakai Y., Matsumoto S., Maki K., Watabe E., Tawara S., et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother 44 (2000) 614-618
21. Schaffner A., and Bohler A. Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism. Mycoses 36 (1993) 421-424
22. Sugar A.M., and Liu X.P. Interactions of itraconazole with amphotericin B in the treatment of murine invasive candidiasis. J Infect Dis 177 (1998) 1660-1663
23. Kretschmar M., Buchheidt D., Hof H., and Nichterlein T. Galactomannan enzyme immunoassay for monitoring systemic infection with Aspergillus fumigatus in mice. Diagn Microbiol Infect Dis 41 (2001) 107-112
24. Wallace T.L., Paetznick V., Cossum P.A., Lopez-Berestein G., Rex J.H., and Anaissie E. Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice. Antimicrob Agents Chemother 41 (1997) 2238-2243
25. Schmidt A. Animal models of aspergillosis - also useful for vaccination strategies?. Mycoses 45 (2002) 38-40
26. Sivak O., Bartlett K., and Wasan K.M. Heat-treated fungizone retains amphotericin B antifungal activity without renal toxicity in rats infected with Aspergillus fumigatus. Pharmacol Res 21 (2004) 1564-1566
27. Sivak O., Bartlett K., Risovic V., Choo E., Marra F., Batty Jr. D.S., et al. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis. J Pharm Sci 93 (2004) 1382-1389
28. Wiederhold N.P., Kontoyiannis D.P., Chi J., Prince R.A., Tam V.H., and Lewis R.E. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 190 (2004) 1464-1471
29. Singh G., Imai J., Clemons K.V., and Stevens D.A. Efficacy of caspofungin against central nervous system Aspergillus fumigatus infection in mice determined by TaqMan PCR and CFU methods. Antimicrob Agents Chemother 49 (2005) 1369-1376